Chemical structure of molecule PF-06939999 Pfizer SAM-competitive PRMT5 inhibitor

oral SAM-competitive PRMT5 inhibitor

Ph. I candidate for solid tumors (adv. or met.)

SBDD utilizing PRMT5:MEP50 w/ A9145C

Molecular Cancer Therapy

Pfizer Oncology

10.   The Pfizer SAM-competitive PRMT5 inhibitor, PF-06939999 is a Ph. I clinical candidate in dose escalation in solid tumors. Ph. I data has been reported showing signs of early efficacy with cytopenias as…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.